Titulo:
Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados
.
Guardado en:
0121-7372
2462-991X
32
2023-10-18
228
234
Revista Repertorio de Medicina y Cirugía - 2020
info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
| id |
metarevistapublica_fucsalud_revistarepertoriodemedicinaycirugia_98_article_1228 |
|---|---|
| record_format |
ojs |
| spelling |
Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados Mora Padilla, Edmundo Ordoñez Vasquez, Mario Jesús Luna Caffroni, Jackelineth Casanova Libreros , Rosangela carcinoma epitelial de ovario quimioterapia adyuvante efectos adversos epithelial ovarian carcinoma adjuvant chemotherapy adverse effects 32 3 Artículo de revista Journal article 2023-10-18 08:34:43 2023-10-18 08:34:43 2023-10-18 application/pdf text/html application/epub+zip text/xml audio/mpeg Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud Revista Repertorio de Medicina y Cirugía 0121-7372 2462-991X https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/1228 10.31260/RepertMedCir.01217372.1228 https://doi.org/10.31260/RepertMedCir.01217372.1228 https://creativecommons.org/licenses/by-nc-sa/4.0/ Revista Repertorio de Medicina y Cirugía - 2020 228 234 International Agency for Research on Cancer. Global Cancer Observatory [Internet]. World Health Organization; 2021 [Consultado 2021]. Available from: https://gco.iarc.fr/ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. https://doi.org/10.3322/caac.21254 Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy Resistance in Advanced Ovarian Cancer Patients. Biomark Cancer. 2019;11:1179299X1986081. https://doi.org/10.1177/1179299X19860815. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. http://dx.doi.org/10.1016/j.bpobgyn.2016.08.006 Lei Z, Wang Y, Wang J, Wang K, Tian J, Zhao Y, et al. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer. JAMA Netw open. 2020;3(8):e2013940. doi: 10.1001/jamanetworkopen.2020.13940 Monk BJ, Randall LM, Grisham RN. The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer. Am Soc Clin Oncol Educ B. 2019;39:e141–51. doi: 10.1200/EDBK_239007 Trimbos JB. Surgical treatment of early-stage ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41(2017):60–70. http://dx.doi.org/10.1016/j.bpobgyn.2016.10.001 Bois A Du, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234–44. https://doi.org/10.1002/cncr.24149. Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer. Hematol Oncol Clin North Am. 2018;32(6):943–64. https://doi.org/10.1016/j.hoc.2018.07.010 Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. Front Immunol. 2020;11: 577869. doi: 10.3389/fimmu.2020.577869 Broekman KE, van Kruchten M, van Tinteren H, Sessa C, Jalving M, Reyners AKL. Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores. ESMO Open. 2021;6(4):100229. https://doi.org/10.1016/j.esmoop.2021.100229 Isabelle RC, Isabelle TF, Eric PL, Liu JF, Selle F, Poveda AM, et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patientswith advanced platinum-resistant or -refractory ovarian cancer. J Clin Oncol. 2016;34(36):4345–53. doi: 10.1200/JCO.2016.67.1891 Murphy M, Martin G, Mahmoudjafari Z, Bivona C, Grauer D, Henry D. Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer. J Oncol Pharm Pract. 2020;26(7):1566–74. https://doi.org/10.1177/1078155219899460 Du Bois A, Lück HJ, Meier W et al. No TitCarboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.le. Semin Onco. 1997;24(5):s15–52. Coleman RL, Hennessy BT, Coleman RL, Markman M. Fallopian, Including Cancer, Tube Cancer, Primary Peritoneal. NCCN. 2021;1. Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. Precision targeted therapy of ovarian cancer. J Control Release. 2016;243:250–68. http://dx.doi.org/10.1016/j.jconrel.2016.10.014 Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495–505. doi: 10.1056/NEJMoa1810858 Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194–200. https://doi.org/10.1200/JCO.2003.02.153. Huang CY, Cheng M, Lee NR, Huang HY, Lee WL, Chang WH, et al. Comparing paclitaxel-"carboplatin with paclitaxel-"cisplatin as the front-line chemotherapy for patients with FIGO IIIC serous-type tubo-ovarian cancer. Int J Environ Res Public Health. 2020;17(7):2213. https://doi.org/10.3390/ijerph17072213. https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/1228/2088 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/1228/2472 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/1228/2506 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/1228/2487 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/1228/2507 info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_2df8fbb1 http://purl.org/redcol/resource_type/ART info:eu-repo/semantics/publishedVersion http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Text Publication |
| institution |
FUNDACIÓN UNIVERSITARIA DE CIENCIA DE LA SALUD |
| thumbnail |
https://nuevo.metarevistas.org/FUNDACIONUNIVERSITARIADECIENCIADELASALUD/logo.png |
| country_str |
Colombia |
| collection |
Revista Repertorio de Medicina y Cirugía |
| title |
Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados |
| spellingShingle |
Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados Mora Padilla, Edmundo Ordoñez Vasquez, Mario Jesús Luna Caffroni, Jackelineth Casanova Libreros , Rosangela carcinoma epitelial de ovario quimioterapia adyuvante efectos adversos epithelial ovarian carcinoma adjuvant chemotherapy adverse effects |
| title_short |
Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados |
| title_full |
Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados |
| title_fullStr |
Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados |
| title_full_unstemmed |
Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados |
| title_sort |
quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados |
| author |
Mora Padilla, Edmundo Ordoñez Vasquez, Mario Jesús Luna Caffroni, Jackelineth Casanova Libreros , Rosangela |
| author_facet |
Mora Padilla, Edmundo Ordoñez Vasquez, Mario Jesús Luna Caffroni, Jackelineth Casanova Libreros , Rosangela |
| topic |
carcinoma epitelial de ovario quimioterapia adyuvante efectos adversos epithelial ovarian carcinoma adjuvant chemotherapy adverse effects |
| topic_facet |
carcinoma epitelial de ovario quimioterapia adyuvante efectos adversos epithelial ovarian carcinoma adjuvant chemotherapy adverse effects |
| citationvolume |
32 |
| citationissue |
3 |
| publisher |
Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud |
| ispartofjournal |
Revista Repertorio de Medicina y Cirugía |
| source |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/1228 |
| language |
|
| format |
Article |
| rights |
https://creativecommons.org/licenses/by-nc-sa/4.0/ Revista Repertorio de Medicina y Cirugía - 2020 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 |
| type_driver |
info:eu-repo/semantics/article |
| type_coar |
http://purl.org/coar/resource_type/c_6501 |
| type_version |
info:eu-repo/semantics/publishedVersion |
| type_coarversion |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| type_content |
Text |
| publishDate |
2023-10-18 |
| date_accessioned |
2023-10-18 08:34:43 |
| date_available |
2023-10-18 08:34:43 |
| url |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/1228 |
| url_doi |
https://doi.org/10.31260/RepertMedCir.01217372.1228 |
| issn |
0121-7372 |
| eissn |
2462-991X |
| doi |
10.31260/RepertMedCir.01217372.1228 |
| citationstartpage |
228 |
| citationendpage |
234 |
| url2_str_mv |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/1228/2088 |
| url3_str_mv |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/1228/2472 |
| url5_str_mv |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/1228/2506 |
| url4_str_mv |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/1228/2487 |
| url7_str_mv |
https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/1228/2507 |
| _version_ |
1811201549929545728 |